- Home
- KNOP vs TCRX Comparison
KNOP vs TCRX Comparison
Compare KNOP & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNOP
- TCRX
- Stock Information
- Founded
- KNOP 2013
- TCRX 2018
- Country
- KNOP United Kingdom
- TCRX United States
- Employees
- KNOP N/A
- TCRX N/A
- Industry
- KNOP Marine Transportation
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- KNOP Consumer Discretionary
- TCRX Health Care
- Exchange
- KNOP Nasdaq
- TCRX Nasdaq
- Market Cap
- KNOP 187.6M
- TCRX 170.1M
- IPO Year
- KNOP 2013
- TCRX 2021
- Fundamental
- Price
- KNOP $5.91
- TCRX $2.40
- Analyst Decision
- KNOP
- TCRX Strong Buy
- Analyst Count
- KNOP 0
- TCRX 5
- Target Price
- KNOP N/A
- TCRX $11.40
- AVG Volume (30 Days)
- KNOP 104.2K
- TCRX 544.4K
- Earning Date
- KNOP 02-24-2025
- TCRX 03-05-2025
- Dividend Yield
- KNOP 1.76%
- TCRX N/A
- EPS Growth
- KNOP N/A
- TCRX N/A
- EPS
- KNOP N/A
- TCRX N/A
- Revenue
- KNOP $299,790,000.00
- TCRX $9,362,000.00
- Revenue This Year
- KNOP $7.66
- TCRX N/A
- Revenue Next Year
- KNOP $1.75
- TCRX $5.14
- P/E Ratio
- KNOP N/A
- TCRX N/A
- Revenue Growth
- KNOP 4.75
- TCRX N/A
- 52 Week Low
- KNOP $4.94
- TCRX $2.38
- 52 Week High
- KNOP $9.11
- TCRX $9.69
- Technical
- Relative Strength Index (RSI)
- KNOP 51.68
- TCRX 25.27
- Support Level
- KNOP $5.87
- TCRX $2.60
- Resistance Level
- KNOP $6.13
- TCRX $2.85
- Average True Range (ATR)
- KNOP 0.23
- TCRX 0.17
- MACD
- KNOP 0.02
- TCRX 0.00
- Stochastic Oscillator
- KNOP 56.25
- TCRX 2.41
About KNOP KNOT Offshore Partners LP Common Units representing Limited Partner Interests
KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.